- 執筆（排名不分先后）吳欣桐（四川大學華西醫院）、陳子怡（中山大學附屬第一醫院）、馮莉（中南大學湘雅醫院）、劉潔（四川省人民醫院）、劉曉蓉（廣州醫科大學附屬第二醫院）、孟紅梅（吉林大學第一醫院）、秦炯（北京大學人民醫院）、喬梁（首都醫科大學宣武醫院）、任連坤（首都醫科大學宣武醫院）、邵曉秋（首都醫科大學附屬北京天壇醫院）、王群（首都醫科大學附屬北京天壇醫院）、王藝（復旦大學附屬兒科醫院）、王玉平（首都醫科大學宣武醫院河北醫院）、肖波（中南大學湘雅醫院）、徐惠琴（溫州醫科大學附屬第一醫院）、謝旭芳（南昌大學第一附屬醫院）、朱國行（復旦大學附屬華山醫院）、周東（四川大學華西醫院）;
中華醫學會神經病學分會腦電圖與癲癇學組,
Email: zhoudong66@yahoo.de
Copyright ? the editorial department of Journal of Epilepsy of West China Medical Publisher. All rights reserved
| 1. | GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 2019, 18(5): 459-480. |
| 2. | Li S, Wang Y, Wang W, et al. The national comprehensive governance for epilepsy prevention and control in China. Epilepsia Open, 2022, 7(1): 27-35. |
| 3. | GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol, 2024, 23(4): 344-381. |
| 4. | Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A, 2004, 101(26): 9861-9866. |
| 5. | Buckley K, Kelly RB. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol, 1985, 100(4): 1284-1294. |
| 6. | L?scher W, Gillard M, Sands ZA, et al. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs, 2016, 30(11): 1055-1077. |
| 7. | Dibbens LM, Hodgson BL, Helbig KL, et al. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam. Epilepsy Res, 2012, 101(3): 277-279. |
| 8. | Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 2008, 54(4): 715-720. |
| 9. | KEPPRA XR (levetiracetam) extended-release tablets. Initial U. S. Approval: 1999. FDA Approved Labeling text dated Jul 2013. |
| 10. | Epilepsies in children, young people and adults NICE guideline. Published: 27 April 2022. Last updated: 30 January 2025. |
| 11. | 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 中國成人局灶性癲癇規范化診治指南. 中華神經科雜志, 2022, 55(12): 1341-1352. |
| 12. | 顧翠, 楊美麗, 王繼華, 等. 左乙拉西坦在癲癇治療中的應用進展. 中國臨床醫生雜志, 2017, 45(3): 24-27. |
| 13. | 楊黎, 董憲喆, 齊曉漣, 等. 左乙拉西坦在臨床應用中療效與安全性的研究進展. 中國新藥雜志, 2021, 30(7): 607-610. |
| 14. | Khuda I, Aljaafari D. Epilepsy in pregnancy: a comprehensive literature review and suggestions for saudi practitioners. Neurosciences (Riyadh), 2018, 23(3): 185-193. |
| 15. | Ben-Menachem E, Mameni?kien? R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology, 2016, 87(3): 314-323. |
| 16. | Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol, 2011, 664(1-3): 36-44. |
| 17. | Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016, 57(2): 201-209. |
| 18. | Nevitt SJ, Sudell M, Cividini S, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 2022, 4(4): CD011412. |
| 19. | Kim JH, Lee SK, Loesch C, et al. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: a long-term, randomized, open-label trial. Epilepsia, 2017, 58(4): e70-e74. |
| 20. | Arnold S, Laloyaux C, Schulz AL, et al. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial. Epilepsy Res, 2020, 166: 106404. |
| 21. | Hu TY, Wang HQ, Zhang WP, et al. Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy. Epilepsy Res, 2020, 167: 106433. |
| 22. | Chen YK, Li WZ, Lu CF, et al. Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials. E Clinical Medicine, 2024, 70: 102513. |
| 23. | O'Brien TJ, Borghs S, He QJ, et al. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. Epilepsia, 2020, 61(4): 636-646. |
| 24. | Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia, 2012, 3(1): 111-119. |
| 25. | Moseley BD, Sperling MR, Asadi-Pooya AA, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res, 2016, 127: 179-185. |
| 26. | Chu H, Zhang X, Shi J, et al. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol, 2023, 270(10): 4713-4728. |
| 27. | K?lvi?inen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. Epilepsia, 2016, 57(2): 210-21. |
| 28. | 中國抗癲癇協會. 臨床診療指南: 癲癇病分冊(2023修訂版). 北京: 人民出版社, 2023. |
| 29. | Lattanzi S, Chiesa V, Di Gennaro G, et al. (2024). Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. Neurol Sci, 2024, 45(9): 4519-4527. |
| 30. | Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, 2021, 397(10282): 1375-1386. |
| 31. | Kanemura H, Sano F, Tando T, et al. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. Brain Dev, 2013, 35(5): 386-391. |
| 32. | Strzelczyk A, Zaveta C, von Podewils F, et al. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia, 2021, 62(12): 2994-3004. |
| 33. | Pereira ARO, Le?o IA, Dias LA, et al. Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy: a systematic review and meta-analysis. Epilepsy Behav, 2025, 171: 110512. |
| 34. | Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia, 2018, 59(8): 1549-1556. |
| 35. | Fonseca E, Guzmán L, Quintana M, et al. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav, 2020, 102: 106657. |
| 36. | Rosenfeld WE, Benbadis S, Edrich P, et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res, 2009, 85(1): 72-80. |
| 37. | Pe?a-Ceballos J, Moloney PB, Kilbride RD, et al. Oligoepilepsy and lifelong seizure susceptibility in epilepsy with generalized tonic-clonic seizures alone: Experience at an adult tertiary center. Epilepsy Res, 2024, 202: 107362. |
| 38. | Hesdorffer, DC, Logroscino, G, Cascino, G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology, 1998, 50(3): 735-741. |
| 39. | Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet, 2020, 395(10231): 1217-1224. |
| 40. | Lyttle MD, Rainford NEA, Gamble C, et al. levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet, 2019, 393(10186): 2125-2134. |
| 41. | Wu PP, Cao BR, Tian FY, et al. Development of SV2A ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil. Neurosci Bull, 2024, 40(5): 594-608. |
| 42. | Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia, 2016, 57(2): 201-209. |
| 43. | Moalong KMC, Espiritu AI, Fernandez MLL. Efficacy and tolerability of intravenous brivaracetam for status epilepticus: a systematic review. J Neurol Sci, 2020, 413: 116799. |
| 44. | Martellino C, Lagana A, Atanasio G, et al. The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus. Epilepsy Behav, 2023, 148: 109464. |
| 45. | Chung S, Szaflarski JP, Choi EJ, et al. A systematic review of seizure clusters: Prevalence, risk factors, burden of disease and treatment patterns. Epilepsy Res, 2021, 177: 106748. |
| 46. | Gujjar AR, Nandhagopal R, Jacob PC, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study. Seizure, 2017, 49: 8-12. |
| 47. | Szaflarski JP, Sadek A, Greve, B et al. Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity. Epilepsy Behav, 2020, 109: 107127. |
| 48. | Orlandi N, d'Orsi G, Pauletto G, et al. A retrospective multicentric study on the effectiveness of intravenous brivaracetam in seizure clusters: data from the Italian experience. Seizure, 2023, 108: 72-80. |
| 49. | Sharawat IK, Murugan VK, Bhardwaj S et al. Efficacy and safety of phenytoin and levetiracetam for acute symptomatic seizures in children with acute encephalitis syndrome: an open label, randomised controlled trial. Seizure, 2024, 118: 110-116. |
| 50. | Wang YL, Wang YQ, Wang HF, et al. Effect of levetiracetam and valproate on late-onset post-traumatic seizures. Acta Epileptol, 2023, 5(1): 10. |
| 51. | Maschio M, Maialetti A, Mocellini C, et al. Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study. Front Neurol, 2020, 11: 813. |
| 52. | Szaflarski JP, Besson H, D'Souza W, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol, 2024, 271(6): 3169-3185. |
| 53. | Wang QH, Cao JJ, Wang YY, et al. Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra. Seizure, 2022, 95: 64-74. |
| 54. | Liu LY, Liu F, Wang QH, et al. Confirming the contribution and genetic spectrum of de novo mutation in infantile spasms: evidence from a Chinese cohort. Mol Genet Genomic Med, 2021, 9(6): e1689. |
| 55. | Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology, 2007, 69(3): 250-254. |
| 56. | Gilad R. Management of seizures following a stroke: what are the options? Drugs Aging, 2012, 29(7): 533-538. |
| 57. | D Consoli, D Bosco, P Postorino, et al. levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc Dis, 2012, 34(4): 282-3289. |
| 58. | 唐青青, 楊秋妹, 胡慧. 丙戊酸鈉聯合左乙拉西坦治療老年腦卒中后癲癇的臨床分析. 老年醫學與保健, 2024, 30(3): 677-682. |
| 59. | Lattanzi S, Canafoglia L, Canevini MP, et al. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Seizure, 2022, 97: 37-42. |
| 60. | Szaflarski JP, Besson H, D'Souza W, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol, 2024, 271(6): 3169-3185. |
| 61. | Lattanzi S, Cagnetti C, Foschi N, et al. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology, 2016, 86(14): 1344-1352. |
| 62. | Brandt C, Klein P, Badalamenti V, et al. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. Epilepsy Behav, 2020, 103(Pt A): 106864. |
| 63. | Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav, 2021, 118: 107939. |
| 64. | Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav, 2015, 52(Pt A): 165-168. |
| 65. | Abraira L, Salas-Puig J, Quintana M, et al. Overnight switch from levetiracetam to brivaracetam. Safety and tolerability. Epilepsy Behav Rep, 2021, 16: 100504. |
| 66. | Villanueva V, López-González FJ, Mauri JA, et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand, 2019, 139(4): 360-368. |
| 67. | Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia, 2002, 43(7): 697-702. |
| 68. | Svalheim, S. , Taub?ll, E. , Luef, G, et al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy & Behavior, 2009, 16(2): 281–287. |
| 69. | Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia, 2014, 55(3): 27-31. |
| 70. | Stockis A, Rolan P. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol, 2013, 53(12): 1313-1321. |
| 71. | Veroniki AA, Cogo E, Rios P, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med, 2017, 15(1): 95. |
| 72. | Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018, 17(6): 530-538. |
| 73. | Margulis AV, Hernandez-Diaz S, McElrath T, et al. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One, 2019, 14(8): e0214180. |
| 74. | Bromley RL, Calderbank R, Cheyne CP, et al. UK epilepsy and pregnancy register: cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology, 2016, 87(18): 1943-1953. |
| 75. | Stjerna S, Huber-Mollema Y, Tomson T, et al. Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol. Epilepsy Behav, 2024, 159: 110024. |
| 76. | Devin, JE, O’Shaughnessy F, Sardana, M, et al. The use of newer anti-seizure medicines in women with epilepsy in pregnancy: a case series. Epilepsy Behav Rep, 2025, 29: 100741. |
| 77. | Paolini SL, Pilato M, Rajasekaran V, et al. Outcomes in three cases after brivaracetam treatment during pregnancy. Acta Neurol Scand, 2020, 141: 438-441. |
| 78. | Landmark CJ, Rektorli L, Burns ML, et al. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. Epileptic Disord, 2021, 23: 426-431. |
| 79. | Hahn W, M?ller L, Menzler K, et al. Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature. Neurol Res Pract, 2024, 6(1): 17. |
| 80. | Navarro CE. A healthy outcome of a pregnant woman with drug-resistant juvenile myoclonic epilepsy treated with brivaracetam. Neurol Sci, 2023, 44(2): 753-755. |
| 81. | Brodie MJ, Whitesides J, Schiemann J, et al. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies. Epilepsy Res, 2016, 127: 114-118. |
| 82. | Bianco CD, Placidi F, Liguori C, et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: a retrospective study. Epilepsy Behav, 2019, 94: 178-182. |
| 83. | Li J, Shlobin NA, Thijs RD, et al. Antiseizure Medications and cardiovascular events in older people with epilepsy in the Canadian longitudinal study on aging. JAMA Neurol, 2024, 81(11): 1178-1186. |
| 84. | Mayer J, Fawzy AM, Bisson A, et al. Epilepsy and the risk of adverse cardiovascular events: a nationwide cohort study. Eur J Neurol, 2024, 31(3): e16116. |
| 85. | Mintzer S, Yi M, Hegarty S, et al. Hyperlipidemia in patients newly treated with anticonvulsants: a population study. Epilepsia, 2020, 61(2): 259-266. |
| 86. | Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia, 2012, 53(1): 120-128. |
| 87. | Mintzer S, Miller R, Shah K, et al. Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. Epilepsy Behav, 2016, 58: 127-32. |
| 88. | Li Y, Su S, Zhang M, et al. Risk assessment of arrhythmias related to three antiseizure medications: a systematic review and single-arm meta-analysis. Front Neurol, 2024, 15: 1295368. |
| 89. | Mintzer S, Trinka E, Kraemer G, et al. Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly. Epilepsia, 2018, 59(10): 1899-1907. |
| 90. | Rosillon D, Astruc B, Hulhoven R, et al. Effect of brivaracetam on cardiac repolarisation–a thorough QT study. Curr Med Res Opin, 2008, 24(8): 2327-2337. |
| 91. | Hassan MA, Awad AA, Marey A, et al. Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: a systematic review and meta-analysis. Neurol Sci, 2025, 46(8): 3525-3536. |
| 92. | Wang SR, Sun H, Wang ZX, et al. Adjunctive treatment for pediatric focal epilepsy: a systematic review. Eur J Clin Pharmacol, 2025, 81(4): 507-523. |
| 93. | Ahadi P, Nasiri J, Ghazavi MR, et al. A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: an open-label randomized controlled trial. J Res Pharm Pract, 2020, 9(2): 68-72. |
| 94. | Tacke M, Borggraefe I, Gerstl L, et al. Effects of levetiracetam and Sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure, 2018, 56: 115-120. |
| 95. | 楊志仙. 睡眠中癲癇性電持續狀態的研究進展. 中國抗癲癇協會腦電圖與神經電生理分會?第七屆CAAE腦電圖與神經電生理大會會刊, 2020: 25-26. |
| 96. | 唐漆, 劉文春. 睡眠中癲癇性電持續狀態的現狀及研究進展. 神經疾病與精神衛生, 2025, 25(4): 258-263. |
| 97. | Larsson PG, Bakke KA, Bj?rn?s H, et al. The effect of levetiracetam on focal nocturnal epileptiform activity during sleep--a placebo-controlled double-blind cross-over study. Epilepsy Behav, 2012, 24(1): 44-8. |
| 98. | Chen XQ, Zhang WN, Yang ZX, et al. Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. Pediatr Neurol, 2014, 50(3): 243-249. |
| 99. | Caraballo RH, Reyes G, Chacón S, et al. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: a study of 42 patients. Epilepsy Behav, 2024, 150: 109561. |
| 100. | Russo A, Pruccoli J, Cesaroni CA, et al. Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence. Seizure, 2022, 102: 120-124. |
| 101. | Visa-Re?é N, Raspall-Chaure M, Paredes-Carmona F, et al. Clinical experience with brivaracetam in a series of 46 children. Epilepsy Behav, 2020, 107: 107067. |
| 102. | Kim HJ, Kim SH, Kang HC, et al. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome. Pediatr Neurol, 2014, 51(4): 527-531. |
| 103. | Rathaur BR, Garg RK, Malhotra HS, et al. Lennox-Gastaut syndrome: a prospective follow-up study. J Neurosci Rural Pract, 2017, 8(2): 225-227. |
| 104. | Willems LM, Bertsche A, B?sebeck F, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol, 2018, 9: 569. |
| 105. | Nissenkorn A, Tzadok M, Bar-Yosef O, et al. Treatment with brivaracetam in children - the experience of a pediatric epilepsy center. Epilepsy Behav, 2019, 101(Pt A): 106541. |
| 106. | levisohn PM, Mintz M, Hunter SJ, et al. N01103 levetiracetam study group: neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia, 2009, 50(11): 2377-2389. |
| 107. | Lagae L, Klotz KA, Fogarasi A, et al. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open-label, follow-up trial. Epilepsia, 2023, 64(11): 2934-2946. |
| 108. | Floricel EF, Reichel PE, Dickson N, et al. Treatment with brivaracetam has no apparent long-term effects on body weight in pediatric patients with epilepsy. Epilepsia Open, 2024, 9(6): 2230-2240. |
| 109. | Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther, 2000, 85(2): 77-85. |
| 110. | UCB Pharma S. A. (比利時). 左乙拉西坦片說明書: [S]. 2016. |
| 111. | Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord, 2019, 12: 1756286419873518. |
| 112. | Moseley BD, Chanteux H, Nicolas JM, et al. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res, 2020, 163: 106327. |
| 113. | Moseley BD, Otoul C, Staelens L, et al. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019, 158: 106218. |
| 114. | 江西青峰藥業有限公司. 布立西坦片說明書: [S]. 2024. |
| 115. | Brockm?ller J, Thomsen T, Wittstock M, et al. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther, 2005, 77(6): 529-541. |
| 116. | He Z, Liu C, Lin L, Feng G, et al. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database. Seizure, 2024, 117: 253-260. |
| 117. | Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug-induced liver injury associated with antiseizure medications from the FDA adverse event reporting system (FAERS). Epilepsy Behav, 2021, 117: 107832. |
| 118. | LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Levetiracetam [Updated 2019 Apr 18]. |
| 119. | Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol, 2013, 53(6): 633-641. |
| 120. | LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Brivaracetam [Updated 2017 Oct 2]. |
| 121. | Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet, 2004, 43(11): 707-724. |
| 122. | Sweatman J, Mahdi SA, Lonsdale DO, et al. Levetiracetam dosing in continuous renal replacement therapy: a systematic review and development of a novel pharmacokinetic model to optimise dosing in critically ill patients: do recommended doses achieve therapeutic drug concentrations? J Intensive Care Soc, 2025, 26(2): 193-204. |
| 123. | Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, et al. Incidence of acute renal failure in patients using levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf, 2022, 45(7): 781-790. |
| 124. | Yau K, Burneo JG, Jandoc R, et al. Population-based study of risk of AKI with levetiracetam. Clin J Am Soc Nephrol, 2019, 14(1): 17-26. |
| 125. | Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol, 2012, 52(12): 1927-1933. |
- 1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 2019, 18(5): 459-480.
- 2. Li S, Wang Y, Wang W, et al. The national comprehensive governance for epilepsy prevention and control in China. Epilepsia Open, 2022, 7(1): 27-35.
- 3. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol, 2024, 23(4): 344-381.
- 4. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A, 2004, 101(26): 9861-9866.
- 5. Buckley K, Kelly RB. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol, 1985, 100(4): 1284-1294.
- 6. L?scher W, Gillard M, Sands ZA, et al. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs, 2016, 30(11): 1055-1077.
- 7. Dibbens LM, Hodgson BL, Helbig KL, et al. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam. Epilepsy Res, 2012, 101(3): 277-279.
- 8. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 2008, 54(4): 715-720.
- 9. KEPPRA XR (levetiracetam) extended-release tablets. Initial U. S. Approval: 1999. FDA Approved Labeling text dated Jul 2013.
- 10. Epilepsies in children, young people and adults NICE guideline. Published: 27 April 2022. Last updated: 30 January 2025.
- 11. 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 中國成人局灶性癲癇規范化診治指南. 中華神經科雜志, 2022, 55(12): 1341-1352.
- 12. 顧翠, 楊美麗, 王繼華, 等. 左乙拉西坦在癲癇治療中的應用進展. 中國臨床醫生雜志, 2017, 45(3): 24-27.
- 13. 楊黎, 董憲喆, 齊曉漣, 等. 左乙拉西坦在臨床應用中療效與安全性的研究進展. 中國新藥雜志, 2021, 30(7): 607-610.
- 14. Khuda I, Aljaafari D. Epilepsy in pregnancy: a comprehensive literature review and suggestions for saudi practitioners. Neurosciences (Riyadh), 2018, 23(3): 185-193.
- 15. Ben-Menachem E, Mameni?kien? R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology, 2016, 87(3): 314-323.
- 16. Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol, 2011, 664(1-3): 36-44.
- 17. Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016, 57(2): 201-209.
- 18. Nevitt SJ, Sudell M, Cividini S, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 2022, 4(4): CD011412.
- 19. Kim JH, Lee SK, Loesch C, et al. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: a long-term, randomized, open-label trial. Epilepsia, 2017, 58(4): e70-e74.
- 20. Arnold S, Laloyaux C, Schulz AL, et al. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial. Epilepsy Res, 2020, 166: 106404.
- 21. Hu TY, Wang HQ, Zhang WP, et al. Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy. Epilepsy Res, 2020, 167: 106433.
- 22. Chen YK, Li WZ, Lu CF, et al. Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials. E Clinical Medicine, 2024, 70: 102513.
- 23. O'Brien TJ, Borghs S, He QJ, et al. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. Epilepsia, 2020, 61(4): 636-646.
- 24. Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia, 2012, 3(1): 111-119.
- 25. Moseley BD, Sperling MR, Asadi-Pooya AA, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res, 2016, 127: 179-185.
- 26. Chu H, Zhang X, Shi J, et al. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol, 2023, 270(10): 4713-4728.
- 27. K?lvi?inen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. Epilepsia, 2016, 57(2): 210-21.
- 28. 中國抗癲癇協會. 臨床診療指南: 癲癇病分冊(2023修訂版). 北京: 人民出版社, 2023.
- 29. Lattanzi S, Chiesa V, Di Gennaro G, et al. (2024). Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. Neurol Sci, 2024, 45(9): 4519-4527.
- 30. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, 2021, 397(10282): 1375-1386.
- 31. Kanemura H, Sano F, Tando T, et al. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. Brain Dev, 2013, 35(5): 386-391.
- 32. Strzelczyk A, Zaveta C, von Podewils F, et al. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia, 2021, 62(12): 2994-3004.
- 33. Pereira ARO, Le?o IA, Dias LA, et al. Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy: a systematic review and meta-analysis. Epilepsy Behav, 2025, 171: 110512.
- 34. Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia, 2018, 59(8): 1549-1556.
- 35. Fonseca E, Guzmán L, Quintana M, et al. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav, 2020, 102: 106657.
- 36. Rosenfeld WE, Benbadis S, Edrich P, et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res, 2009, 85(1): 72-80.
- 37. Pe?a-Ceballos J, Moloney PB, Kilbride RD, et al. Oligoepilepsy and lifelong seizure susceptibility in epilepsy with generalized tonic-clonic seizures alone: Experience at an adult tertiary center. Epilepsy Res, 2024, 202: 107362.
- 38. Hesdorffer, DC, Logroscino, G, Cascino, G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology, 1998, 50(3): 735-741.
- 39. Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet, 2020, 395(10231): 1217-1224.
- 40. Lyttle MD, Rainford NEA, Gamble C, et al. levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet, 2019, 393(10186): 2125-2134.
- 41. Wu PP, Cao BR, Tian FY, et al. Development of SV2A ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil. Neurosci Bull, 2024, 40(5): 594-608.
- 42. Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia, 2016, 57(2): 201-209.
- 43. Moalong KMC, Espiritu AI, Fernandez MLL. Efficacy and tolerability of intravenous brivaracetam for status epilepticus: a systematic review. J Neurol Sci, 2020, 413: 116799.
- 44. Martellino C, Lagana A, Atanasio G, et al. The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus. Epilepsy Behav, 2023, 148: 109464.
- 45. Chung S, Szaflarski JP, Choi EJ, et al. A systematic review of seizure clusters: Prevalence, risk factors, burden of disease and treatment patterns. Epilepsy Res, 2021, 177: 106748.
- 46. Gujjar AR, Nandhagopal R, Jacob PC, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study. Seizure, 2017, 49: 8-12.
- 47. Szaflarski JP, Sadek A, Greve, B et al. Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity. Epilepsy Behav, 2020, 109: 107127.
- 48. Orlandi N, d'Orsi G, Pauletto G, et al. A retrospective multicentric study on the effectiveness of intravenous brivaracetam in seizure clusters: data from the Italian experience. Seizure, 2023, 108: 72-80.
- 49. Sharawat IK, Murugan VK, Bhardwaj S et al. Efficacy and safety of phenytoin and levetiracetam for acute symptomatic seizures in children with acute encephalitis syndrome: an open label, randomised controlled trial. Seizure, 2024, 118: 110-116.
- 50. Wang YL, Wang YQ, Wang HF, et al. Effect of levetiracetam and valproate on late-onset post-traumatic seizures. Acta Epileptol, 2023, 5(1): 10.
- 51. Maschio M, Maialetti A, Mocellini C, et al. Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study. Front Neurol, 2020, 11: 813.
- 52. Szaflarski JP, Besson H, D'Souza W, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol, 2024, 271(6): 3169-3185.
- 53. Wang QH, Cao JJ, Wang YY, et al. Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra. Seizure, 2022, 95: 64-74.
- 54. Liu LY, Liu F, Wang QH, et al. Confirming the contribution and genetic spectrum of de novo mutation in infantile spasms: evidence from a Chinese cohort. Mol Genet Genomic Med, 2021, 9(6): e1689.
- 55. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology, 2007, 69(3): 250-254.
- 56. Gilad R. Management of seizures following a stroke: what are the options? Drugs Aging, 2012, 29(7): 533-538.
- 57. D Consoli, D Bosco, P Postorino, et al. levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc Dis, 2012, 34(4): 282-3289.
- 58. 唐青青, 楊秋妹, 胡慧. 丙戊酸鈉聯合左乙拉西坦治療老年腦卒中后癲癇的臨床分析. 老年醫學與保健, 2024, 30(3): 677-682.
- 59. Lattanzi S, Canafoglia L, Canevini MP, et al. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Seizure, 2022, 97: 37-42.
- 60. Szaflarski JP, Besson H, D'Souza W, et al. Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis. J Neurol, 2024, 271(6): 3169-3185.
- 61. Lattanzi S, Cagnetti C, Foschi N, et al. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology, 2016, 86(14): 1344-1352.
- 62. Brandt C, Klein P, Badalamenti V, et al. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. Epilepsy Behav, 2020, 103(Pt A): 106864.
- 63. Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav, 2021, 118: 107939.
- 64. Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav, 2015, 52(Pt A): 165-168.
- 65. Abraira L, Salas-Puig J, Quintana M, et al. Overnight switch from levetiracetam to brivaracetam. Safety and tolerability. Epilepsy Behav Rep, 2021, 16: 100504.
- 66. Villanueva V, López-González FJ, Mauri JA, et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand, 2019, 139(4): 360-368.
- 67. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia, 2002, 43(7): 697-702.
- 68. Svalheim, S. , Taub?ll, E. , Luef, G, et al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy & Behavior, 2009, 16(2): 281–287.
- 69. Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia, 2014, 55(3): 27-31.
- 70. Stockis A, Rolan P. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol, 2013, 53(12): 1313-1321.
- 71. Veroniki AA, Cogo E, Rios P, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med, 2017, 15(1): 95.
- 72. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018, 17(6): 530-538.
- 73. Margulis AV, Hernandez-Diaz S, McElrath T, et al. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One, 2019, 14(8): e0214180.
- 74. Bromley RL, Calderbank R, Cheyne CP, et al. UK epilepsy and pregnancy register: cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology, 2016, 87(18): 1943-1953.
- 75. Stjerna S, Huber-Mollema Y, Tomson T, et al. Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol. Epilepsy Behav, 2024, 159: 110024.
- 76. Devin, JE, O’Shaughnessy F, Sardana, M, et al. The use of newer anti-seizure medicines in women with epilepsy in pregnancy: a case series. Epilepsy Behav Rep, 2025, 29: 100741.
- 77. Paolini SL, Pilato M, Rajasekaran V, et al. Outcomes in three cases after brivaracetam treatment during pregnancy. Acta Neurol Scand, 2020, 141: 438-441.
- 78. Landmark CJ, Rektorli L, Burns ML, et al. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. Epileptic Disord, 2021, 23: 426-431.
- 79. Hahn W, M?ller L, Menzler K, et al. Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature. Neurol Res Pract, 2024, 6(1): 17.
- 80. Navarro CE. A healthy outcome of a pregnant woman with drug-resistant juvenile myoclonic epilepsy treated with brivaracetam. Neurol Sci, 2023, 44(2): 753-755.
- 81. Brodie MJ, Whitesides J, Schiemann J, et al. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies. Epilepsy Res, 2016, 127: 114-118.
- 82. Bianco CD, Placidi F, Liguori C, et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: a retrospective study. Epilepsy Behav, 2019, 94: 178-182.
- 83. Li J, Shlobin NA, Thijs RD, et al. Antiseizure Medications and cardiovascular events in older people with epilepsy in the Canadian longitudinal study on aging. JAMA Neurol, 2024, 81(11): 1178-1186.
- 84. Mayer J, Fawzy AM, Bisson A, et al. Epilepsy and the risk of adverse cardiovascular events: a nationwide cohort study. Eur J Neurol, 2024, 31(3): e16116.
- 85. Mintzer S, Yi M, Hegarty S, et al. Hyperlipidemia in patients newly treated with anticonvulsants: a population study. Epilepsia, 2020, 61(2): 259-266.
- 86. Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia, 2012, 53(1): 120-128.
- 87. Mintzer S, Miller R, Shah K, et al. Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. Epilepsy Behav, 2016, 58: 127-32.
- 88. Li Y, Su S, Zhang M, et al. Risk assessment of arrhythmias related to three antiseizure medications: a systematic review and single-arm meta-analysis. Front Neurol, 2024, 15: 1295368.
- 89. Mintzer S, Trinka E, Kraemer G, et al. Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly. Epilepsia, 2018, 59(10): 1899-1907.
- 90. Rosillon D, Astruc B, Hulhoven R, et al. Effect of brivaracetam on cardiac repolarisation–a thorough QT study. Curr Med Res Opin, 2008, 24(8): 2327-2337.
- 91. Hassan MA, Awad AA, Marey A, et al. Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: a systematic review and meta-analysis. Neurol Sci, 2025, 46(8): 3525-3536.
- 92. Wang SR, Sun H, Wang ZX, et al. Adjunctive treatment for pediatric focal epilepsy: a systematic review. Eur J Clin Pharmacol, 2025, 81(4): 507-523.
- 93. Ahadi P, Nasiri J, Ghazavi MR, et al. A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: an open-label randomized controlled trial. J Res Pharm Pract, 2020, 9(2): 68-72.
- 94. Tacke M, Borggraefe I, Gerstl L, et al. Effects of levetiracetam and Sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure, 2018, 56: 115-120.
- 95. 楊志仙. 睡眠中癲癇性電持續狀態的研究進展. 中國抗癲癇協會腦電圖與神經電生理分會?第七屆CAAE腦電圖與神經電生理大會會刊, 2020: 25-26.
- 96. 唐漆, 劉文春. 睡眠中癲癇性電持續狀態的現狀及研究進展. 神經疾病與精神衛生, 2025, 25(4): 258-263.
- 97. Larsson PG, Bakke KA, Bj?rn?s H, et al. The effect of levetiracetam on focal nocturnal epileptiform activity during sleep--a placebo-controlled double-blind cross-over study. Epilepsy Behav, 2012, 24(1): 44-8.
- 98. Chen XQ, Zhang WN, Yang ZX, et al. Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. Pediatr Neurol, 2014, 50(3): 243-249.
- 99. Caraballo RH, Reyes G, Chacón S, et al. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: a study of 42 patients. Epilepsy Behav, 2024, 150: 109561.
- 100. Russo A, Pruccoli J, Cesaroni CA, et al. Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence. Seizure, 2022, 102: 120-124.
- 101. Visa-Re?é N, Raspall-Chaure M, Paredes-Carmona F, et al. Clinical experience with brivaracetam in a series of 46 children. Epilepsy Behav, 2020, 107: 107067.
- 102. Kim HJ, Kim SH, Kang HC, et al. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome. Pediatr Neurol, 2014, 51(4): 527-531.
- 103. Rathaur BR, Garg RK, Malhotra HS, et al. Lennox-Gastaut syndrome: a prospective follow-up study. J Neurosci Rural Pract, 2017, 8(2): 225-227.
- 104. Willems LM, Bertsche A, B?sebeck F, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol, 2018, 9: 569.
- 105. Nissenkorn A, Tzadok M, Bar-Yosef O, et al. Treatment with brivaracetam in children - the experience of a pediatric epilepsy center. Epilepsy Behav, 2019, 101(Pt A): 106541.
- 106. levisohn PM, Mintz M, Hunter SJ, et al. N01103 levetiracetam study group: neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia, 2009, 50(11): 2377-2389.
- 107. Lagae L, Klotz KA, Fogarasi A, et al. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open-label, follow-up trial. Epilepsia, 2023, 64(11): 2934-2946.
- 108. Floricel EF, Reichel PE, Dickson N, et al. Treatment with brivaracetam has no apparent long-term effects on body weight in pediatric patients with epilepsy. Epilepsia Open, 2024, 9(6): 2230-2240.
- 109. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther, 2000, 85(2): 77-85.
- 110. UCB Pharma S. A. (比利時). 左乙拉西坦片說明書: [S]. 2016.
- 111. Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord, 2019, 12: 1756286419873518.
- 112. Moseley BD, Chanteux H, Nicolas JM, et al. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res, 2020, 163: 106327.
- 113. Moseley BD, Otoul C, Staelens L, et al. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019, 158: 106218.
- 114. 江西青峰藥業有限公司. 布立西坦片說明書: [S]. 2024.
- 115. Brockm?ller J, Thomsen T, Wittstock M, et al. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther, 2005, 77(6): 529-541.
- 116. He Z, Liu C, Lin L, Feng G, et al. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database. Seizure, 2024, 117: 253-260.
- 117. Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug-induced liver injury associated with antiseizure medications from the FDA adverse event reporting system (FAERS). Epilepsy Behav, 2021, 117: 107832.
- 118. LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Levetiracetam [Updated 2019 Apr 18].
- 119. Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol, 2013, 53(6): 633-641.
- 120. LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Brivaracetam [Updated 2017 Oct 2].
- 121. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet, 2004, 43(11): 707-724.
- 122. Sweatman J, Mahdi SA, Lonsdale DO, et al. Levetiracetam dosing in continuous renal replacement therapy: a systematic review and development of a novel pharmacokinetic model to optimise dosing in critically ill patients: do recommended doses achieve therapeutic drug concentrations? J Intensive Care Soc, 2025, 26(2): 193-204.
- 123. Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, et al. Incidence of acute renal failure in patients using levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf, 2022, 45(7): 781-790.
- 124. Yau K, Burneo JG, Jandoc R, et al. Population-based study of risk of AKI with levetiracetam. Clin J Am Soc Nephrol, 2019, 14(1): 17-26.
- 125. Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol, 2012, 52(12): 1927-1933.